Predictmedix AI Unveils Safe Entry Stations to Delegates from 30 Nations at D-30 Event in New Delhi

   |   Press Releases

Toronto, Ontario – November 6, 2023 – Predictmedix AI Inc.  (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) (the “Company” or “Predictmedix”), a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI) is proud to announce that it introduced its state-of-the-art Safe Entry Stations to delegates from 30 countries during the D-30 event in New Delhi, India. This event signifies a pivotal step forward in the global fight against drug addiction and the disabilities caused by drug abuse. It symbolizes the collaboration of 30 nations recognized by the United Nations for their dedicated efforts to address drug addiction on a worldwide scale.

In New Delhi, countries and organizations from around the world united to tackle the critical issue of drug abuse. D-30 aimed to foster international unity and cooperation in combating addiction and promoting a safer and healthier future for all. The event provided a platform for sharing knowledge, experiences, and innovative solutions to overcome the challenges posed by drug addiction.


Predictmedix AI’s Safe Entry Stations took center stage as a pioneering solution for enhancing safety and well-being in various environments. These stations utilize advanced artificial intelligence to provide rapid, non-invasive health assessments, including impairment detection contributing to safer workplaces and communities.

Safe Entry Stations were also deployed at a prominent government vocational training institute in New Delhi where it was impactful in creating a safe environment for students and trainees. The impact made by the technology in the education / learning segment was also showcased at the event.

We are pleased to provide external links to the corporate presentation by key personnel in India including the Safe Entry booklet that was provided to all the guests and participants at the event:



  • Validation / Testimonial of Safe Entry Station at a prominent government training institute in Delhi. The video was also showcased at the event:




Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix AI, expressed his enthusiasm about the company’s participation in the D-30 event, stating, “Our mission at Predictmedix AI is to leverage cutting-edge technology to address pressing global health and safety concerns. We are honored to have showcased our Safe Entry Stations to the representatives of 30 nations committed to combatting drug addiction and promoting a safer world. We believe that our AI-driven solutions can play a vital role in this collective effort. Furthermore, making an impact in the education/skill development segment at a prominent institute in India opens another vertical for our technology.”

Predictmedix AI’s Safe Entry Stations have demonstrated great potential in numerous applications, from workplaces and healthcare settings to transportation hubs and public events. They provide real-time health assessments and are designed to help identify individuals who may pose a risk due to drug impairment or other health issues.


Predictmedix AI continues to lead the way in developing innovative health and safety solutions powered by artificial intelligence. The company’s participation in the D-30 event underscores its commitment to global well-being and its role as a key player in the fight against drug addiction and its associated disabilities.

About Colonel G. Srikumar, S.M. (Retd.)

Colonel G. Srikumar, S.M. (Retd.), is a highly accomplished individual with a multifaceted career spanning the military, media, and cutting-edge health technology. With a remarkable military background, Col. Srikumar has earned accolades and recognition for his unwavering commitment and service to his nation, including the prestigious Sena Medal.


As an esteemed advisor to the Newspaper Association of India, Col. Srikumar brings his wealth of knowledge to the realm of media and journalism. His guidance and insights contribute significantly to the association’s mission in fostering ethical journalism, freedom of the press, and upholding journalistic standards.


In addition to his role with the Newspaper Association, Col. G. Srikumar has taken on a new and exciting challenge as the Director of Predictmedix India Pvt Ltd. In this capacity, he plays a pivotal role in the implementation of cutting-edge health technology solutions. Col. Srikumar’s leadership ensures that Predictmedix continues to make advancements in AI-driven health screening and impairment detection, contributing to a safer and healthier society.


To receive company news, please sign up for alerts at


About Predictmedix AI Inc.

Predictmedix AI Inc. (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company’s Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI’s proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on TwitterInstagram or LinkedIn. To receive company news, please sign up for alerts at

Public Relations Contact

For further media information or to set up an interview, please contact:

Nelson Hudes

Communications International (905) 660 9155

Dr. Rahul Kushwah (647) 889 6916

Caution Regarding Forward-Looking Information:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: “The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.